CJC-1295 + Ipamorelin
5+5mg
Pre-blended vial containing CJC-1295 (no DAC), a modified GRF(1-29) analogue, and Ipamorelin, a selective ghrelin receptor pentapeptide agonist. The two compounds are widely co-investigated in pulsatile growth hormone release research, where the GHRH analogue and GHRP are studied for their complementary mechanisms at the somatotroph. Lyophilised powder, third-party tested.
Published research on CJC-1295 + Ipamorelin is indexed on PubMed. See our full UK buyer's guide for Ipamorelin.
Intended Use: Strictly for in-vitro laboratory research. Not for use in humans or animals. Not to be used in foods, drugs, or medical diagnostics. This product has not been evaluated by the MHRA or FDA. Buyer assumes full responsibility for safe handling and regulatory compliance.
Content-verified
Purity
LAB
Certified
SAME
Day Ship
Quantity
Add £2.01 more for free UK delivery
Damaged or lost? Free reshipment guaranteed
Bacteriostatic Water 10ml
Required to reconstitute lyophilised peptides.
Research Use Only
This product is intended strictly for research and laboratory use only. Not for human consumption, medical use, or diagnostic purposes.
Certificate of Analysis
Third-party tested
Lyophilised Stability
24 months
Sealed at -20°C, light-protected
Reconstituted Stability
Up to 3 months
Stored at 2-8°C after mixing
Cold-Chain Shipping
Always
Dry-cold pack, Royal Mail Tracked 24
Important Notice
All compounds are sold individually and do not include research supplies. Products are provided in lyophilised (powder) form and require proper reconstitution before use in research settings.
Related Products
CJC-1295 + Ipamorelin Price (UK)
CJC-1295 + Ipamorelin is supplied in 2 vial sizes, priced from £42.99 for 5+5mg to £59.99 for 10+10mg. Every size ships from our UK facility with the same third-party HPLC certificate published on this page. UK delivery is £4.50 by Royal Mail Tracked 24, or free once your basket reaches £45 (£2.01 away at this price). Orders placed before 2pm on a working day are dispatched the same day.
| Vial | Price | Cost per mg | Availability |
|---|---|---|---|
| CJC-1295 + Ipamorelin 5+5mgThis page | £42.99 | £4.30 | In stock |
| CJC-1295 + Ipamorelin 10+10mg | £59.99 | £3.00Best value | In stock |
Prices are in GBP and shown per vial as supplied, lyophilised, for in-vitro laboratory research only. Cost per mg is given so researchers can compare vial sizes on a like-for-like basis. Stock and pricing on this table are read live from our inventory, so they match the basket. See our FAQ for delivery and payment options, and quality & testing for how each batch is verified.
Product Specifications
Research Overview
This is a single vial containing two distinct growth hormone secretagogues, CJC-1295 without DAC and Ipamorelin, supplied pre-blended at 5mg of each. The two act on separate receptors, which is the entire reason they are studied together rather than as alternatives to one another.
CJC-1295 without DAC is more precisely described as tetrasubstituted GRF(1-29), a 29-amino-acid fragment of growth hormone releasing hormone carrying four substitutions (D-Ala at position 2, Gln at 8, Ala at 15 and Leu at 27). The substitution at position 2 is the functionally important one: it blocks cleavage by dipeptidyl peptidase-4, the protease that degrades native GRF within minutes. It binds the GHRH receptor on the pituitary somatotroph and signals through the cAMP/PKA pathway. Because it lacks the drug affinity complex, it does not covalently bind serum albumin and its action remains short, which is precisely what makes it useful for studying pulse shape rather than sustained elevation.
Ipamorelin is a synthetic pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2) that acts at a completely different target, the ghrelin receptor GHS-R1a. Raun and colleagues (Eur J Endocrinol, 1998) characterised it as the first growth hormone releasing peptide with selectivity approaching that of GHRH itself, reporting growth hormone release without the accompanying ACTH and cortisol elevation seen with earlier compounds in the class such as GHRP-6 and hexarelin. That selectivity is the single most cited property of the molecule.
Pairing a GHRH analogue with a GHS-R1a agonist is a long-standing design in secretagogue research, following the work of Bowers and colleagues showing that the two classes produce a greater combined response than either alone. The usual mechanistic explanation is that the GHRH arm drives somatotroph cAMP signalling while the GHRP arm additionally attenuates somatostatin tone, so the two are acting on different limbs of the same axis rather than competing for one receptor. Supplied as lyophilised powder for in-vitro laboratory research only.
Product Specifications
Laboratory Handling
- Store the lyophilised vial at -20°C, protected from light and moisture. Hold reconstituted solution at 2-8°C.
- Reconstitute with bacteriostatic water introduced slowly down the inner glass wall, never onto the lyophilised cake. Swirl gently, never shake or vortex.
- Both components are in the same vial and go into solution together, so the blend cannot be separated after reconstitution. Study designs needing the two compounds at independent concentrations should use the separate CJC-1295 and Ipamorelin vials instead.
- Work under aseptic conditions with sterile syringes and alcohol-swabbed stoppers. Avoid repeated freeze-thaw cycles and aliquot reconstituted stock for reproducibility.
Frequently Asked Questions
What is CJC-1295 + Ipamorelin?
This is a pre-blended research vial co-formulating two mechanistically distinct growth hormone secretagogues: CJC-1295 (no DAC) 5mg, a tetrasubstituted 29-residue analogue of the GHRH(1-29) fragment (D-Ala2, Gln8, Ala15, Leu27; 3367.9 g/mol) acting at the GHRH receptor, and Ipamorelin 5mg, a pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH₂; 711.85 g/mol) acting as a selective agonist at the ghrelin receptor GHS-R1a. The two receptors sit on the same anterior pituitary somatotroph but engage different signalling, Gs-cAMP for the GHRH receptor against Gq-phospholipase C-calcium for GHS-R1a, which is why the pairing is the standard two-receptor design in growth hormone release research. Co-lyophilisation into one vial means a single reconstitution puts both compounds into solution at a fixed 1:1 mass ratio, which is far from equimolar: because ipamorelin is the much smaller molecule, 5mg of it is roughly 7.0 µmol against roughly 1.5 µmol of the GRF analogue. The blend itself has no dedicated literature; the evidence base is two separate single-agent literatures. Supplied as lyophilised powder for in-vitro research use only.
CJC-1295 + Ipamorelin vs the Components Alone
The scientific case for the pairing rests on receptor complementarity. CJC-1295 (no DAC) drives the GHRH-receptor axis, the physiological on signal for somatotroph GH synthesis and release, characterised in the CJC-1295 literature including the human pharmacology reported by Teichman and colleagues (J Clin Endocrinol Metab, 2006) for the DAC-conjugated molecule. Ipamorelin drives the ghrelin-receptor axis, the amplifying input characterised by Raun and colleagues (Eur J Endocrinol, 1998), and is selective for GH release over ACTH, cortisol and prolactin, which is what distinguishes it from GHRP-2 and GHRP-6 in a combination context. Because the two receptors converge on the same cell through different second messengers, co-stimulation is studied for additive or synergistic GH release, and dual-pathway designs are common in somatotroph biology. The honest caveat is that combination claims trace to those two separate single-agent literatures plus the general GHRH-GHRP synergy literature; no controlled study of this specific blend has been published. The blend fixes the ratio permanently at reconstitution, so any design needing independent concentrations, a single-agent control arm, or attribution of an effect to one receptor requires the individual vials, which we stock separately.
CJC-1295 + Ipamorelin Research Applications
The blend is used in preclinical endocrine research designs that would otherwise run the two compounds from separate preparations: dual-receptor somatotroph stimulation studies, pulsatile GH release kinetics where a GHRH-receptor pulse and a ghrelin-receptor input are applied together, and downstream IGF-1 axis work. The practical value of the co-formulated vial is procedural, one reconstitution, one fill volume, one in-use window and one certificate of analysis, rather than any property arising from the mixture itself. The component literatures remain the reference points: GRF-analogue receptor pharmacology and pulsatility for the CJC-1295 side, and selective GHS-R1a agonism with a clean ACTH, cortisol and prolactin profile for the ipamorelin side. Researchers needing to vary the GHRH-to-GHS ratio, run either compound alone as a control, or assign an observed response to one receptor should use the individual vials instead.
Reconstitution Guide
Treat the vial as a single 10mg preparation with one fill volume set by the concentration your protocol specifies. Allow the vial and the bacteriostatic water to reach room temperature, then sterilise both rubber stoppers with an alcohol swab. Inject the bacteriostatic water slowly down the inner glass wall of the vial, never directly onto the lyophilised powder, and swirl gently in a slow circular motion until fully dissolved. Never shake or vortex, the 29-residue GRF analogue is the shear-sensitive component and agitation reduces recovery of intact peptide. The solution should be clear and colourless. Remember that the components cannot be separated after reconstitution and that the equal-mass blend is far from equimolar, roughly 7.0 µmol of ipamorelin against 1.5 µmol of CJC-1295. Label the vial with the fill volume, concentration and reconstitution date, and refrigerate immediately.
See our full peptide reconstitution guide and reconstitution calculator for step-by-step protocol.
Storage Instructions
Lyophilised vials should be stored at -20°C, protected from light and moisture, and remain stable for up to 24 months. Once reconstituted with bacteriostatic water, store the solution at 2-8°C and use within approximately 4 weeks, preparing single-use aliquots at -20°C for anything longer. Because both components share one reconstitution date in a co-formulated vial, the less stable component governs the whole preparation: the GRF analogue is the fragile partner, degradation-prone in dilute standing solution and sensitive to freeze-thaw cycling, while the D-amino-acid-stabilised ipamorelin is comparatively robust. Aliquot at reconstitution rather than repeatedly puncturing one stock, and handle under sterile laboratory conditions throughout.
Frequently Asked Questions
Research References
- Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults (Teichman et al., J Clin Endocrinol Metab, 2006)
- Ipamorelin, the first selective growth hormone secretagogue (Raun et al., Eur J Endocrinol, 1998)
Related Research Compounds
CJC-1295 + Ipamorelin
5+5mg · £42.99